A classification of drug action based on therapeutic effects

Journal of Clinical Pharmacology

Volumn 36, Issue 8, 1996, Pages 669-673

  Bjornsson, Thorir D ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b Jefferson Medical College ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIINFECTIVE AGENT; ANTILIPEMIC AGENT; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; DIGITALIS GLYCOSIDE; DIURETIC AGENT; DRUG; HORMONE; LOCAL ANESTHETIC AGENT; METHYLXANTHINE DERIVATIVE; NEUROLEPTIC AGENT; NEUROMUSCULAR BLOCKING AGENT; VACCINE;

CLINICAL TRIAL; DRUG CLASSIFICATION; DRUG DEVELOPMENT; DRUG EFFECT; DRUG MECHANISM; MEDICAL EDUCATION; PATHOPHYSIOLOGY; REVIEW;

EID: 0029815040     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1996.tb04234.x     Document Type: Review

References (17)

1. Gilman AG, Rall TW, Nies AS, Taylor P (eds.): Goodman and Gilman's The Pharmacological Basis of Therapeutics. Eighth edition. New York: Pergamon Press, 1990.
2. American Hospital Formulary Service: AHFS 95 Drug Information. Bethesda, MD: American Society of Hospital Pharmacists, 1995.
3. WHO Collaborating Centre for Drug Statistics Methodology: Guidelines for ATC Classification. Oslo, Norway: World Health Association, 1990.
4. Pharmaprojects: How Drugs Work: User Guide. Now York: Pharmaprojects, 1994.
5. Laurence D, Carpenter J: A Dictionary of Pharmacology and Clinical Drug Evaluation. London, England: UCL Press Limited, 1994.
6. Spector R: Pharmacodynamics. In, Spector R (ed.): The Scientific Basic of Clinical Pharmacology: Principles and Examples. Boston, MA: Little, Brown and Company, 1986; 103-111.
7. Grahme-Smith DG, Aronson JK: Oxford Textbook of Clinical Pharmacology and Drug Therapy. Oxford, England: Oxford University Press, 1992.
8. McGahan AM: Industry structure and competitive advantage. Harvard Business Review 1994; 72:115-124.
9. Temple R: Trends in pharmaceutical development. Drug Information J 1993; 27:355-366.
10. Luce BR: Cost-effectiveness analysis: obstacles to standardization and its use in regulating pharmaceuticals. PharmacoEconomics 1993; 3:1-9.
11. Freestone DS: Reflections on pharmaceutical company project portfolio management. Drug Information J 1994; 28:641-646.
12. Spilker B: Evaluating a portfolio of investigational medicine projects. In, Multinational Pharmaceutical Companies: Principles and Practices. Second edition. New York: Raven Press, 1994; 365-399.
13. Gonnella JS, Hornbrook MC, Louis DZ: Staging of disease: a case-mix measurement. JAMA 1984; 251:637-644.
14. Gonnella JS, Hojat M, Erdmann JB, Veloski JJ: What have we learned, and where do we go from here? In, Gonnella JS, Hojat M, Erdmann JB, Veloski JJ (eds.): Assessment Measures in Medical School, Residency, and Practice: The Connections. New York: Springer, 1993; 155-173.
15. Beeson PB: Changes in medical therapy during the past century. Medicine 1980; 59:79-99.
16. Newbold BB: How are medicines discovered? In: Burley DM, Clarke JM, Lasagna L (eds.): Pharmaceutical Medicine. Second edition. London, England: Edward Arnold, 1993; 1-11.
17. Wurtman RJ, Bettiker RL: The slowing of treatment discovery, 1965-1995. Nature Medicine 1995; 1:1122-1125.